Brokerages predict that Exact Sciences Corporation (NASDAQ:EXAS) will announce earnings per share (EPS) of ($0.33) for the current quarter, according to Zacks. Five analysts have issued estimates for Exact Sciences Corporation’s earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.31). Exact Sciences Corporation posted earnings per share of ($0.36) in the same quarter last year, which would suggest a positive year over year growth rate of 8.3%. The business is scheduled to report its next quarterly earnings report on Wednesday, October 25th.

According to Zacks, analysts expect that Exact Sciences Corporation will report full-year earnings of ($1.19) per share for the current financial year, with EPS estimates ranging from ($1.28) to ($1.01). For the next year, analysts expect that the business will report earnings of ($0.78) per share, with EPS estimates ranging from ($1.03) to ($0.49). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Exact Sciences Corporation.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.10. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. The business had revenue of $57.65 million during the quarter, compared to the consensus estimate of $47.73 million.

A number of equities research analysts recently weighed in on EXAS shares. Vetr downgraded shares of Exact Sciences Corporation from a “hold” rating to a “sell” rating and set a $34.70 price objective for the company. in a research report on Wednesday, July 12th. Canaccord Genuity boosted their target price on shares of Exact Sciences Corporation from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, May 31st. Zacks Investment Research raised shares of Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a research note on Tuesday, June 27th. Roth Capital boosted their target price on shares of Exact Sciences Corporation from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, July 26th. Finally, Goldman Sachs Group, Inc. (The) set a $33.00 target price on shares of Exact Sciences Corporation and gave the company a “neutral” rating in a research note on Monday, May 1st. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $40.51.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/11/0-33-eps-expected-for-exact-sciences-corporation-exas-this-quarter.html.

Shares of Exact Sciences Corporation (EXAS) traded up 1.11% during midday trading on Friday, hitting $37.46. 177,965 shares of the stock traded hands. Exact Sciences Corporation has a one year low of $13.05 and a one year high of $42.18. The firm has a 50-day moving average price of $37.54 and a 200 day moving average price of $28.68. The stock’s market cap is $4.46 billion.

In other news, CFO Jeffrey Thomas Elliott sold 5,846 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $39.41, for a total value of $230,390.86. Following the completion of the sale, the chief financial officer now directly owns 19,861 shares of the company’s stock, valued at approximately $782,722.01. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP D Scott Coward sold 1,987 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $35.21, for a total transaction of $69,962.27. Following the completion of the sale, the senior vice president now directly owns 57,603 shares of the company’s stock, valued at $2,028,201.63. The disclosure for this sale can be found here. Corporate insiders own 4.00% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Fortaleza Asset Management Inc. bought a new stake in shares of Exact Sciences Corporation during the second quarter worth $106,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Exact Sciences Corporation by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after buying an additional 600 shares in the last quarter. Financial Architects Inc raised its stake in shares of Exact Sciences Corporation by 90.0% in the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after buying an additional 2,035 shares in the last quarter. Johnson Financial Group Inc. raised its stake in shares of Exact Sciences Corporation by 25.9% in the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after buying an additional 1,000 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Exact Sciences Corporation by 66.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,052 shares of the medical research company’s stock worth $179,000 after buying an additional 2,013 shares in the last quarter. 84.86% of the stock is owned by institutional investors.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Get a free copy of the Zacks research report on Exact Sciences Corporation (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.